{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hepatitis-a/prescribing-information/anti-emetics/","result":{"pageContext":{"chapter":{"id":"0ee2b156-78a9-52f6-ab80-fff22c46ff66","slug":"anti-emetics","fullItemName":"Anti-emetics","depth":2,"htmlHeader":"<!-- begin field aad4c2ac-389a-43fe-8b42-5cdda5ddfc30 --><h2>Anti-emetics</h2><!-- end field aad4c2ac-389a-43fe-8b42-5cdda5ddfc30 -->","summary":"","htmlStringContent":"<!-- begin item 19d8d926-c5c8-498d-9868-2a7f041df1c9 --><!-- end item 19d8d926-c5c8-498d-9868-2a7f041df1c9 -->","topic":{"id":"29ac65ab-afdd-58a1-bb07-9c101977d24d","topicId":"580cfa7a-647b-439a-8f8c-493cb6bd4332","topicName":"Hepatitis A","slug":"hepatitis-a","lastRevised":"Last revised in January 2021","chapters":[{"id":"d47cd8cf-fe05-5aa4-997b-01a20519d12f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bbe6550-f4f5-5279-9e9e-04b38f9dc672","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"75791cbd-6d69-555e-83e8-9ac8cca25c50","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c0ae1a2d-febe-5ec7-821a-0616062456ee","slug":"changes","fullItemName":"Changes"},{"id":"434eb73d-f60d-5f1f-ba10-5aa77d904da1","slug":"update","fullItemName":"Update"}]},{"id":"242c9e8c-5867-5598-9168-62160e8ae293","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"6c2f4656-f9e8-56be-aa43-3f6a9aa45aa8","slug":"goals","fullItemName":"Goals"},{"id":"71c0a726-22c7-568b-b925-d10cc97ace3a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"70e8a1cd-fd5b-50d7-8ce4-b6f29981218d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"37bb7a58-62c9-52be-b97c-7b99f8317f12","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"badbd40f-9ce6-5f8a-9f65-8be03bc8d3fe","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ed9f7297-1f33-5365-8e4f-3844542af45d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6a11034-e31c-5039-8ca7-b463c00b2039","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a2206363-5f44-5348-b469-07b49a6a9647","slug":"definition","fullItemName":"Definition"},{"id":"dd1ca873-1bf9-500d-a574-fc92c8589e62","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bdd89354-2f0b-564c-b589-cb043e32b99c","slug":"transmission","fullItemName":"Transmission"},{"id":"8e72bb81-12fd-5a0e-976b-d18d62788974","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ab3f5823-00db-5e27-a434-c323c357ab02","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"e879b74c-3d75-59c5-806e-4b39a6e72901","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"94f8b729-5e94-57ee-b96e-ca1561614640","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"6b32fed7-c15e-5976-adc6-692994cbab9e","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"2503640c-54cf-53e1-b29c-fc9c19cbd52a","slug":"investigations","fullItemName":"Investigations"},{"id":"88a35298-3760-53b6-b4ff-b9e0677b4df3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9ba7b244-14ec-5fd1-9b2b-151b9c48bfab","fullItemName":"Management","slug":"management","subChapters":[{"id":"1a3874e3-8562-5ca6-8c97-4d9a2a009e75","slug":"prevention-of-infection-with-hepatitis-a","fullItemName":"Scenario: Prevention of infection with hepatitis A"},{"id":"49c1d671-61dd-5a60-974f-069b03d80d11","slug":"managing-hepatitis-a-infection","fullItemName":"Scenario: Managing hepatitis A infection"},{"id":"449ffa79-3397-54a1-a4d5-0efa55ee889f","slug":"contact-with-hepatitis-a","fullItemName":"Scenario: Contact with hepatitis A"}]},{"id":"8ffd203a-96db-5a38-a7bd-0186b97b6600","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"7d022e5d-ab4e-50bf-b90f-5611cf3a17db","slug":"hepatitis-a-vaccine","fullItemName":"Hepatitis A vaccine"},{"id":"7d0e86fd-3666-5a09-b539-4497227285ee","slug":"analgesia","fullItemName":"Analgesia"},{"id":"0ee2b156-78a9-52f6-ab80-fff22c46ff66","slug":"anti-emetics","fullItemName":"Anti-emetics"},{"id":"508e578c-aa68-5cdb-aa90-ef8889919c08","slug":"anti-pruritics","fullItemName":"Anti-pruritics"}]},{"id":"bf6b787f-fbb7-5d8d-bd85-cfe063c76fcd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e0bba353-de5a-55b9-9171-a677ecc4b97a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2571e87f-4ad0-5f6d-8c0e-8c9c86054278","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"94bd9363-8cd1-5ba6-8fd3-11f5a3ce29dd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2db0f1a2-7d4b-5fd2-a8bf-db32553e5b89","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"29233885-dedb-5c3b-ba7e-1aae299ecfe2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0a3a365f-c89a-5f1e-8ce5-1078ade19779","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1afe9613-76a4-50b9-8941-c2a2ebec23cc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"8ffd203a-96db-5a38-a7bd-0186b97b6600","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"019161f9-0e7b-52f1-82fa-a5c9a8242596","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field f7dcb307-6f53-43d6-8464-aafb016c33b3 --><h3>Contraindications and cautions</h3><!-- end field f7dcb307-6f53-43d6-8464-aafb016c33b3 -->","summary":"","htmlStringContent":"<!-- begin item b164b47c-44a4-4a57-bb41-aafb016c3324 --><!-- begin field eb6c854e-ca6a-4398-bc56-aafb016c33b3 --><h4>Metoclopramide</h4><ul><li><strong>Metoclopramide should not be used </strong><strong>in people with:</strong><ul><li>Gastrointestinal obstruction, perforation or haemorrhage.</li><li>Confirmed or suspected pheochromocytoma, due to the risk of severe hypertensive episodes.</li><li>History of neuroleptic or metoclopramide-induced tardive dyskinesia.</li></ul></li><li><strong>Metoclopramide should be used with caution </strong><strong>in people with:</strong><ul><li>Liver dysfunction — metoclopramide can be used in people whose metabolic and synthetic function is unaffected (such as in mild hepatitis). However, seek specialist advice before using metoclopramide in people with more severe hepatic impairment, as reduced clearance may increase the risk of gynaecomastia and extrapyramidal adverse effects. The dose should be reduced by 50% in people with cirrhosis.</li><li>Renal impairment — metoclopramide and its metabolites are predominately excreted via the kidneys. In people with severe renal impairment (eGFR less than 30 mL/minute/1.73 m<sup>2</sup>), avoid metoclopramide or use a reduced dose. Accumulation of metoclopramide increases the risk of extrapyramidal adverse effects.</li><li>Epilepsy or Parkinson's disease.</li><li>Pregnancy — published fetal exposure data are limited, but there is no evidence of an increase in congenital malformations in exposed pregnancies, but a possible higher incidence of premature delivery in one small cohort study [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">UKTIS, 2019a</a>]. </li><li>Breastfeeding — the UK Drugs in Lactation Advisory Service states that metoclopramide is compatible with breastfeeding for short-term, low-dose use (dose not exceeding 30 mg a day), but there is insufficient evidence, or clinical experience of use, to guarantee safe use in breastfeeding. See the <a data-hyperlink-id=\"fd955e7f-8436-4946-b341-a993006e6a98\" href=\"http://www.midlandsmedicines.nhs.uk/\">UKMI lactation advisory service</a> website for more information.</li></ul></li></ul><h4>Cyclizine</h4><ul><li><strong>Cyclizine should be used with caution </strong><strong>in people with:</strong><ul><li>Liver dysfunction — cyclizine can be used in people whose metabolic and synthetic function is unaffected (such as in mild hepatitis). However, seek specialist advice before using cyclizine in people with moderate hepatic impairment. It must be avoided in people with severe hepatic impairment, such as those with cirrhosis or encephalopathy who may decompensate, because of its sedative effects.</li><li>Urinary retention, prostatic hypertrophy, angle-closure glaucoma, or pyloroduodenal obstruction — if possible, avoid using sedating antihistamines such as cyclizine because of their significant antimuscarinic activity (particularly in elderly people).</li><li>Epilepsy — avoid cyclizine if possible, as it can reduce the seizure threshold.</li><li>Severe heart failure — avoid using cyclizine if possible, as it may decrease cardiac output.</li><li>Pregnancy — the published data for the safety of cyclizine are limited, but there is no robust evidence of an increased risk of infant congenital malformation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">UKTIS, 2019a</a>]. </li><li>Breastfeeding — the UK Drugs in Lactation Advisory Service states that there is no published evidence of the safety of cyclizine use in breastfeeding, but it may be considered for occasional, short-term use when breastfeeding. Repeated use may cause a risk of sedation of the infant, and may interfere with lactation. See the <a data-hyperlink-id=\"b1bf97d7-2f28-4297-9ec4-a993006e6ab8\" href=\"http://www.midlandsmedicines.nhs.uk/\">UKMI lactation advisory service</a> website for more information.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">North-Lewis, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field eb6c854e-ca6a-4398-bc56-aafb016c33b3 --><!-- end item b164b47c-44a4-4a57-bb41-aafb016c3324 -->","subChapters":[]},{"id":"64413b45-a1f0-57e8-9a0e-cf51ac5f0a75","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field fa1cc59a-5071-4146-b5b2-aafb016c3fa3 --><h3>Adverse effects</h3><!-- end field fa1cc59a-5071-4146-b5b2-aafb016c3fa3 -->","summary":"","htmlStringContent":"<!-- begin item 85ea8a7c-eef0-4245-8578-aafb016c3f5b --><!-- begin field 36962426-c378-4aa6-aeb8-aafb016c3fa3 --><h4>Metoclopramide</h4><ul><li><strong>Metoclopramide is generally well tolerated. </strong><strong>However:</strong><ul><li>Extrapyramidal reactions (usually dystonic) can occur. Most reactions occur within 36 hours of starting and disappear within 24 hours of stopping treatment. The incidence of dystonic reactions is more common in young adults under the age of 20 years.</li><li>Raised serum prolactin levels with prolonged treatment can cause galactorrhoea, irregular periods, and gynaecomastia.</li><li>Neuroleptic malignant syndrome has very rarely been reported with metoclopramide use.</li></ul></li><li><strong>The maximum duration of therapy with metoclopramide is 5 days</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">EMA, 2013</a>].<ul><li>Following a review by the European Medicines Agency, metoclopramide should not be prescribed for more than 5 days. The EMA review confirmed the well-known neurological risks such as short-term extrapyramidal adverse effects. This risk is higher in children, although tardive dyskinesia was reported more often in the elderly, and the risk is increased at high doses or with long-term treatment. The EMA states that the risks outweighed the benefits of metoclopramide treatment in conditions requiring long-term treatment. There have also been very rare cases of serious cardiovascular adverse effects, particularly after injection.</li></ul></li></ul><h4>Cyclizine</h4><ul><li><strong>The most commonly reported adverse effects are </strong><strong>nervous system disorders:</strong><ul><li>Elderly people are particularly susceptible (and so lower doses are recommended).</li><li>Sedating antihistamines may cause drowsiness.</li><li>Anticholinergic adverse effects may also occur, for example, blurred vision and dry mouth.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 36962426-c378-4aa6-aeb8-aafb016c3fa3 --><!-- end item 85ea8a7c-eef0-4245-8578-aafb016c3f5b -->","subChapters":[]},{"id":"661a35f4-0884-5d83-bb8a-ff30e0886dfc","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 5c56a988-3ae2-4223-9947-aafb016c4f37 --><h3>Drug interactions</h3><!-- end field 5c56a988-3ae2-4223-9947-aafb016c4f37 -->","summary":"","htmlStringContent":"<!-- begin item a21ac941-dfe3-4d1e-a59d-aafb016c4ef5 --><!-- begin field 213105a3-1f84-4765-b996-aafb016c4f37 --><p><strong>Key drug interactions include:</strong></p><ul><li><strong>Metoclopramide:</strong><ul><li>Levodopa or dopaminergic agonists — avoid in combination with metoclopramide due to mutual antagonism.</li><li>Anticholinergics and morphine derivatives — may have both a mutual antagonism with metoclopramide on digestive tract motility.</li><li>CNS depressants — sedative effects are potentiated.</li><li>Neuroleptics — additive effect with other neuroleptics on the risk of extrapyramidal disorders.</li><li>Serotonergenics — use of metoclopramide with serotonergic drugs such as SSRIs may increase the risk of serotonin syndrome.</li><li>Digoxin — metoclopramide may decrease digoxin bioavailability. Careful monitoring of digoxin plasma concentration is required.</li><li>Cyclosporine — metoclopramide increases cyclosporine bioavailability. Careful monitoring of cyclosporine plasma concentration is required.</li><li>Strong CYP2D6 inhibitors — metoclopramide levels are increased when co-administered with strong CYP2D6 inhibitors such as fluoxetine and paroxetine. People should therefore be monitored for adverse reactions.</li></ul></li><li><strong>Cyclizine:</strong><ul><li>CNS depressants — additive effects may occur.</li><li>Anticholinergenics/antimuscarinics (including atropine, TCAs and MAOIs) — additive effects may occur.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 213105a3-1f84-4765-b996-aafb016c4f37 --><!-- end item a21ac941-dfe3-4d1e-a59d-aafb016c4ef5 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}